Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn MoreMalignant gliomas account for 70% of primary malignant brain tumors, with an annual incidence of 5/100,000 and more than 14,000 new cases each year. Researchers have identified a specific subpopulation of cells in brain tumors. This subpopulation of cells has the ability of self-renewal, proliferation, and multi-differentiation potential, which is brain tumor stem cells (BTSCs). And the presence of BTSCs may be the root cause of brain tumorigenesis, recurrence, and drug resistance.
Neurospheres are composed of stem cells, progenitor cells, and terminally differentiated cells. During the continuous passages, differentiated cells die quickly, and stem cells proliferate and this process can be repeated. This results in a large, stable population of neural stem cells in the culture system. With this technology, Alfa Cytology can isolate human brain tumor specimens. We apply the direct culture method to obtain BTSCs, identify them, and analyze their biological properties. This can provide you with reliable information for further brain tumor research.
BTSCs have multi-differentiation potential and can be induced to differentiate into a variety of terminally differentiated cells. Alfa Cytology can isolate brain tumor cells from brain tumor tissue specimens and obtain BTSCs after a period of culture with a serum-free medium. Our isolated BTSCs can be passaged, lyophilized, and revived. With high quality, they can meet your different research needs. Please contact our staff for more analysis options for brain tumor stem cells.